R&D When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain & Portugal explains the new methods implemented in the affiliate, and the importance of the company’s research center in Seville,…
R&D Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant growth during a time of economic downturn. Many Spanish companies have disappeared or have been sold in recent years in…
diabetes PMG Pharma, a niche player, with products concentrated in the nephrology/dialysis, injectables and diabetes areas, has concluded distribution agreements with companies from all over the world. “Many are underestimating the Chinese pharmaceutical market but I expect to see a lot of business coming from that country”, tells Horst Peter Endler…
R&D Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui Santos explains this process and how he plans to tackle the tough Portuguese marketplace. Almirall has been in Portugal…
Gubelkian Jose Pereira Leal, Group Leader Head of the Bioinformatics Unit at Instituto Gulbenkian de Ciencia, discusses the institute’s unique selling point, stating that, “researchers will continue to come and stay here based on the excellence of research” that the country, and institute in particular, are currently experiencing. Since its…
R&D Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology, and how it could spark a paradigm shift in the way cancer is treated. Luzitin won the Innovation of the…
Generics As a company focused entirely on innovation, Janssen has remained dedicated to bringing groundbreaking new products to Portugal, ensuring access in Portugal is as stellar as anywhere else. Gisella Dante, General Manager of Janssen Portugal, outlines the affiliate’s strategy to keep investments in Portugal including local partnerships. Would you…
Generics Paulo Lilaia, CEO of Generis Portugal give an insight into the role of generics in the Portuguese marketplace as well as his company’s strategy to expand in both the local and international markets. You are both the President of Apogen and CEO of Generis. How do you balance your…
Generics Nelson Pires, General Manager of Jaba Recordati, the Portuguese affiliate of the Recordati Group, outlines the affiliate’s expansion into the PALOPS markets and demonstrates how the company has grown during a time of market decline. Jaba was a Portuguese-based company until 2006, when it was bought by Recordati, whereupon…
R&D Nuno Arantes-Oliveira, President of P-BIO, Portugal’s Biotechnology Industry Organization, the country’s sole association for biotechnology companies, discusses the state of the biotech industry today in Portugal, and the ways in which the industry can consolidate and attract overseas investment to stimulate growth. After a harsh economic downturn over the…
Biotechnology Despite Portugal’s economic woes, some local companies have been able to adjust accordingly and succeed in this environment. Tecnifar is no exception. The company’s CEO, António Chaves Costa, talks about Tecnifar’s in-licensing strategy, as well as its diversification of investments and future plans for export business. Last year, Tecnifar…
medical tourism Joaquim Cunha, Executive Director of Health Cluster Portugal (HCP), emphasizes Portugal’s need to discover niches in which the country can excel and compete globally, while rebranding its image around the world. He also highlights the drivers behind cluster’s main initiatives: innovation, collaboration/coopetition and internationalization. What is Portugal’s number one…
See our Cookie Privacy Policy Here
